Go Pro
→ Trump's New Dollar (From Porter & Company) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
BioCryst Pharmaceuticals, Inc. stock logo
BCRX
BioCryst Pharmaceuticals
$9.83
$9.68
$6.00
▼
$11.22
$2.51B0.553.29 million shs1.86 million shs
CareDx, Inc. stock logo
CDNA
CareDx
$50.96
+0.3%		$37.41
$12.37
▼
$51.13
$2.63B2.391.26 million shs1.42 million shs
EIKN
Eikon Therapeutics
$11.98
-4.5%		$10.48
$7.90
▼
$17.40
$679.77MN/A485,951 shs324,085 shs
Nektar Therapeutics stock logo
NKTR
Nektar Therapeutics
$73.77
-1.6%		$70.43
$27.87
▼
$109.00
$2.56B1.14618,913 shs450,247 shs
Options Trading Made Easy - Download Now Cover
Options Trading Made Easy - Download Now

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
BioCryst Pharmaceuticals, Inc. stock logo
BCRX
BioCryst Pharmaceuticals
0.00%-2.38%+2.61%+8.02%+14.57%
CareDx, Inc. stock logo
CDNA
CareDx
+0.31%+9.57%+40.15%+124.49%+297.81%
EIKN
Eikon Therapeutics
-4.54%-0.25%+21.26%+16.31%+1,197,999,900.00%
Nektar Therapeutics stock logo
NKTR
Nektar Therapeutics
-1.59%-3.04%+3.39%+13.47%+156.32%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
BioCryst Pharmaceuticals, Inc. stock logo
BCRX
BioCryst Pharmaceuticals
$9.83
$9.68
$6.00
▼
$11.22
$2.51B0.553.29 million shs1.86 million shs
CareDx, Inc. stock logo
CDNA
CareDx
$50.96
+0.3%		$37.41
$12.37
▼
$51.13
$2.63B2.391.26 million shs1.42 million shs
EIKN
Eikon Therapeutics
$11.98
-4.5%		$10.48
$7.90
▼
$17.40
$679.77MN/A485,951 shs324,085 shs
Nektar Therapeutics stock logo
NKTR
Nektar Therapeutics
$73.77
-1.6%		$70.43
$27.87
▼
$109.00
$2.56B1.14618,913 shs450,247 shs
Options Trading Made Easy - Download Now Cover
Options Trading Made Easy - Download Now

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
BioCryst Pharmaceuticals, Inc. stock logo
BCRX
BioCryst Pharmaceuticals
0.00%-2.38%+2.61%+8.02%+14.57%
CareDx, Inc. stock logo
CDNA
CareDx
+0.31%+9.57%+40.15%+124.49%+297.81%
EIKN
Eikon Therapeutics
-4.54%-0.25%+21.26%+16.31%+1,197,999,900.00%
Nektar Therapeutics stock logo
NKTR
Nektar Therapeutics
-1.59%-3.04%+3.39%+13.47%+156.32%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
BioCryst Pharmaceuticals, Inc. stock logo
BCRX
BioCryst Pharmaceuticals
2.67
Moderate Buy$20.60109.56% Upside
CareDx, Inc. stock logo
CDNA
CareDx
2.57
Moderate Buy$47.75-6.30% Downside
EIKN
Eikon Therapeutics
2.38
Hold$25.00108.68% Upside
Nektar Therapeutics stock logo
NKTR
Nektar Therapeutics
2.77
Moderate Buy$141.5091.81% Upside

Current Analyst Ratings Breakdown

Latest EIKN, CDNA, NKTR, and BCRX Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
8/24/2026
Nektar Therapeutics stock logo
NKTR
Nektar Therapeutics
TD Cowen logo
TD Cowen
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeStrong-Buy
8/21/2026
EIKN
Eikon Therapeutics
Cantor Fitzgerald logo
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingOverweight
8/21/2026
Nektar Therapeutics stock logo
NKTR
Nektar Therapeutics
JPMorgan Chase & Co. logo
JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageNeutral$65.00
8/14/2026
EIKN
Eikon Therapeutics
Wedbush logo
Wedbush
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower Price TargetUnderperform$5.00 ➝ $4.00
8/13/2026
CareDx, Inc. stock logo
CDNA
CareDx
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeSell (D+) ➝ Hold (C)
8/6/2026
BioCryst Pharmaceuticals, Inc. stock logo
BCRX
BioCryst Pharmaceuticals
Royal Bank Of Canada logo
Royal Bank Of Canada
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower Price TargetOutperform$14.00 ➝ $13.00
8/6/2026
BioCryst Pharmaceuticals, Inc. stock logo
BCRX
BioCryst Pharmaceuticals
Wedbush logo
Wedbush
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower Price TargetOutperform$21.00 ➝ $20.00
8/6/2026
CareDx, Inc. stock logo
CDNA
CareDx
Zacks Research logo
Zacks Research
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeHold ➝ Strong-Buy
8/6/2026
CareDx, Inc. stock logo
CDNA
CareDx
BTIG Research logo
BTIG Research
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetBuy$45.00 ➝ $60.00
8/3/2026
EIKN
Eikon Therapeutics
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeSell (E-) ➝ Sell (E)
8/3/2026
CareDx, Inc. stock logo
CDNA
CareDx
Craig Hallum logo
Craig Hallum
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeHold ➝ Buy$64.00
(Data available from 8/27/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
BioCryst Pharmaceuticals, Inc. stock logo
BCRX
BioCryst Pharmaceuticals
$874.84M2.87$1.24 per share7.94($1.78) per share-5.52
CareDx, Inc. stock logo
CDNA
CareDx
$379.80M6.94$0.01 per share7,799.31$8.23 per share6.19
EIKN
Eikon Therapeutics
N/AN/AN/AN/A$8.61 per shareN/A
Nektar Therapeutics stock logo
NKTR
Nektar Therapeutics
$55.23M45.60N/AN/A$26.45 per share2.79
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
BioCryst Pharmaceuticals, Inc. stock logo
BCRX
BioCryst Pharmaceuticals
$263.86M-$1.50N/A13.65N/A-40.90%-86.89%66.37%11/2/2026 (Estimated)
CareDx, Inc. stock logo
CDNA
CareDx
-$21.35M$2.0724.6280.89N/A24.23%2.87%2.17%11/3/2026 (Estimated)
EIKN
Eikon Therapeutics
-$324.25M-$4.09N/AN/AN/AN/AN/AN/AN/A
Nektar Therapeutics stock logo
NKTR
Nektar Therapeutics
-$164.08M-$6.70N/AN/AN/A-287.84%-37.87%-25.67%11/5/2026 (Estimated)

Latest EIKN, CDNA, NKTR, and BCRX Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/13/2026Q2 2026
EIKN
Eikon Therapeutics
-$1.61-$1.63-$0.02-$1.63N/AN/A
8/13/2026Q2 2026
Nektar Therapeutics stock logo
NKTR
Nektar Therapeutics
-$1.97-$1.23+$0.74-$1.23$10.43 million$10.13 million
8/5/2026Q2 2026
BioCryst Pharmaceuticals, Inc. stock logo
BCRX
BioCryst Pharmaceuticals
$0.1542$0.30+$0.1458$0.30$183.28 million$218.25 million
7/30/2026Q2 2026
CareDx, Inc. stock logo
CDNA
CareDx
$0.2321$0.37+$0.1379$2.07$114.05 million$131.95 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
BioCryst Pharmaceuticals, Inc. stock logo
BCRX
BioCryst Pharmaceuticals
N/AN/AN/AN/AN/A
CareDx, Inc. stock logo
CDNA
CareDx
N/AN/AN/AN/AN/A
EIKN
Eikon Therapeutics
N/AN/AN/AN/AN/A
Nektar Therapeutics stock logo
NKTR
Nektar Therapeutics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
BioCryst Pharmaceuticals, Inc. stock logo
BCRX
BioCryst Pharmaceuticals
N/A
2.32
2.29
CareDx, Inc. stock logo
CDNA
CareDx
N/A
4.58
4.51
EIKN
Eikon Therapeutics
N/A
9.89
9.89
Nektar Therapeutics stock logo
NKTR
Nektar Therapeutics
N/A
10.42
10.42

Institutional Ownership

CompanyInstitutional Ownership
BioCryst Pharmaceuticals, Inc. stock logo
BCRX
BioCryst Pharmaceuticals
85.88%
CareDx, Inc. stock logo
CDNA
CareDx
N/A
EIKN
Eikon Therapeutics
N/A
Nektar Therapeutics stock logo
NKTR
Nektar Therapeutics
75.88%

Insider Ownership

CompanyInsider Ownership
BioCryst Pharmaceuticals, Inc. stock logo
BCRX
BioCryst Pharmaceuticals
3.80%
CareDx, Inc. stock logo
CDNA
CareDx
2.40%
EIKN
Eikon Therapeutics
N/A
Nektar Therapeutics stock logo
NKTR
Nektar Therapeutics
2.50%
CompanyEmployeesShares OutstandingFree FloatOptionable
BioCryst Pharmaceuticals, Inc. stock logo
BCRX
BioCryst Pharmaceuticals
530255.54 million245.83 millionOptionable
CareDx, Inc. stock logo
CDNA
CareDx
74051.73 million50.49 millionOptionable
EIKN
Eikon Therapeutics
38454.17 millionN/AN/A
Nektar Therapeutics stock logo
NKTR
Nektar Therapeutics
22034.14 million33.29 millionOptionable

Recent News About These Companies

Nektar Therapeutics (NASDAQ:NKTR) Upgraded at TD Cowen
 |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=30985326
AWM Investment Company Inc. Acquires Shares of 20,925 Nektar Therapeutics $NKTR
August 26 at 3:12 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-awm-investment-company-inc-acquires-shares-of-20925-nektar-therapeutics-nktr-2026-08-26/
Nektar Announces Publication in The Lancet of Positive Phase 2b REZOLVE-AD 16-Week Induction Results of Rezpegaldesleukin in Moderate-to-Severe Atopic Dermatitis
August 25 at 8:30 AM  |  prnewswire.comhttps://www.prnewswire.com/news-releases/nektar-announces-publication-in-the-lancet-of-positive-phase-2b-rezolve-ad-16-week-induction-results-of-rezpegaldesleukin-in-moderate-to-severe-atopic-dermatitis-302858888.html
Nektar Therapeutics (NASDAQ:NKTR) Upgraded by TD Cowen to Strong-Buy Rating
August 25 at 6:59 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/analyst-nektar-therapeutics-nasdaq-nktr-upgraded-by-td-cowen-to-strong-buy-rating-2026-08-25/
Nektar Therapeutics (NASDAQ:NKTR) Coverage Initiated at JPMorgan Chase & Co.
August 23, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=30977403
Nektar (NKTR) Q2 2026 Earnings Call Transcript
August 21, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/nektar-nktr-q2-2026-earnings-233402905.html
JPMorgan Chase & Co. Initiates Coverage on Nektar Therapeutics (NASDAQ:NKTR)
August 21, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/jpmorgan-chase-co-initiates-coverage-on-nektar-therapeutics-nasdaqnktr-2026-08-21/
Insider Selling: Nektar Therapeutics (NASDAQ:NKTR) Insider Sells $13,388.28 in Stock
August 21, 2026  |  insidertrades.comhttps://www.insidertrades.com/alerts/nasdaq-nktr-insider-buying-and-selling-2026-08-21/
HC Wainwright Issues Negative Outlook for NKTR Earnings
August 21, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=30973404
Top Nektar Therapeutics Insiders Quietly Cash In on Recent Stock Moves
August 20, 2026  |  tipranks.comhttps://www.tipranks.com/news/insider-trading/top-nektar-therapeutics-insiders-quietly-cash-in-on-recent-stock-moves-insider-trading-news?utm_source=marketbeat.com&utm_medium=referral
Nektar Therapeutics (NASDAQ:NKTR) Insider Jonathan Zalevsky Sells 186 Shares of Stock
August 20, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/nektar-therapeutics-nasdaqnktr-insider-jonathan-zalevsky-sells-186-shares-of-stock-2026-08-20/
Insider Selling: Nektar Therapeutics (NASDAQ:NKTR) CEO Sells $30,087.64 in Stock
August 20, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/insider-selling-nektar-therapeutics-nasdaqnktr-ceo-sells-3008764-in-stock-2026-08-20/
HC Wainwright Issues Pessimistic Forecast for NKTR Earnings
August 19, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/hc-wainwright-issues-pessimistic-forecast-for-nktr-earnings-2026-08-19/
Nektar Therapeutics Initiated at Buy on Rezpeg’s Advancing Pivotal Programs and Solid Cash Runway
August 17, 2026  |  tipranks.comhttps://www.tipranks.com/news/ratings/nektar-therapeutics-initiated-at-buy-on-rezpegs-advancing-pivotal-programs-and-solid-cash-runway-ratings-news?utm_source=marketbeat.com&utm_medium=referral
Nektar Therapeutics (NASDAQ:NKTR) Receives $150.00 Average PT from Analysts
August 17, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=30966210
Nektar Therapeutics (NKTR) Could Be 52% Undervalued After Q2 Earnings Surprise
August 15, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/nektar-therapeutics-nktr-could-52-020915503.html
Nektar Therapeutics (NKTR) Stock Looks Stretched Despite New Phase 3 Trial Launch
August 14, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/nektar-therapeutics-nktr-stock-looks-151217411.html
Nektar: Maintaining 'Strong Buy' Rating Due To REZPEG Catalyst, Another Coming
August 14, 2026  |  seekingalpha.comhttps://seekingalpha.com/article/4936885-nektar-maintaining-strong-buy-rating-due-to-rezpeg-catalyst-another-coming
Nektar Q2 Earnings Beat Estimates, Revenues Lag, Pipeline in Focus
August 14, 2026  |  zacks.comhttps://www.zacks.com/stock/news/2975069/nektar-q2-earnings-beat-estimates-revenues-lag-pipeline-in-focus?cid=cs-stocknewsapi-ft-analyst_blog|earnings_article-2975069
Nektar Therapeutics (NKTR) Q2 2026
August 14, 2026  |  247wallst.comhttps://247wallst.com/companies/nktr/earnings
Nektar: Q2 Earnings Snapshot
August 14, 2026  |  chron.comhttps://www.chron.com/business/article/nektar-q2-earnings-snapshot-22387462.php

New MarketBeat Followers Over Time

Media Sentiment Over Time

BioCryst Pharmaceuticals stock logo

BioCryst Pharmaceuticals NASDAQ:BCRX

$9.83 0.00 (0.00%)
Closing price 08/26/2026 04:00 PM Eastern
Extended Trading
$9.96 +0.13 (+1.36%)
As of 06:13 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

BioCryst Pharmaceuticals, Inc., a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema. It is also developing BCX10013, an oral factor D inhibitor for complement-mediated diseases. The company has collaborations and in-license relationships with the Torii Pharmaceutical Co., Ltd.; Seqirus UK Limited; Shionogi & Co., Ltd.; Green Cross Corporation; National Institute of Allergy and Infectious Diseases; Biomedical Advanced Research and Development Authority; the U.S. Department of Health and Human Services; and The University of Alabama at Birmingham, as well as Albert Einstein College of Medicine of Yeshiva University and Industrial Research, Ltd. BioCryst Pharmaceuticals, Inc. was founded in 1986 and is headquartered in Durham, North Carolina.

CareDx stock logo

CareDx NASDAQ:CDNA

$50.96 +0.16 (+0.31%)
Closing price 08/26/2026 04:00 PM Eastern
Extended Trading
$51.15 +0.19 (+0.37%)
As of 06:21 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

CareDx, Inc. engages in the discovery, development, and commercialization of diagnostic solutions for transplant patients and caregivers in the United States and internationally. It also provides AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients; and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. The company offers Olerup SSP, which is used to type human leukocyte antigen (HLA) alleles based on sequence specific primer technology; QTYPE that enables precision in HLA typing; and Ottr, a transplant patient management software. In addition, it provides AlloSeq Tx, a high-resolution HLA typing solution; AlloSeq cfDNA, a surveillance solution to measure dd-cfDNA in blood; AlloSeq HCT, a solution for chimerism testing for stem cell transplant recipients; Allocell, a surveillance solution that monitors the level of engraftment and persistence of allogeneic cells for patients who have received cell therapy transplants; and XynQAPI cloud-based transplant quality management software, as well as AlloCare, a mobile app that offers a patient-centric resource for transplant recipients. The company offers its products directly to customers, as well as through third-party distributors and sub-distributors. It has a license agreement with Illumina, Inc. for the distribution, development, and commercialization of NGS products and technologies; and Cibiltech SAS to commercialize iBox, a software for the predictive analysis of post-transplantation kidney allograft loss. The company was formerly known as XDx, Inc. and changed its name to CareDx, Inc. in March 2014. The company was incorporated in 1998 and is headquartered in South San Francisco, California.

Eikon Therapeutics NASDAQ:EIKN

$11.98 -0.57 (-4.54%)
Closing price 08/26/2026 04:00 PM Eastern
Extended Trading
$12.25 +0.27 (+2.25%)
As of 04:00 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

We are a late-stage clinical biopharmaceutical company dedicated to building a global, fully-integrated organization developing important, innovative medicines to address serious unmet medical needs. We are led by world-renowned drug developers Dr. Roger M. Perlmutter, M.D., Ph.D., and Dr. Roy Baynes, M.D., Ph.D. Our vision is to become a generational leader, by purposefully integrating traditional biology research with advanced engineering to develop better medicines faster. Our initial focus is oncology, where we are advancing a pipeline of drug candidates targeting areas of high unmet need in large indications. We believe our product candidates reflect strong scientific and clinical potential and could eventually become critical medicines in the treatment paradigm of various cancers. Our Chair and Chief Executive Officer, Dr. Roger M. Perlmutter, M.D., Ph.D., and our Chief Medical Officer, Dr. Roy Baynes, M.D., Ph.D., together have a proven track record of identifying, developing, and commercializing some of the most impactful drugs ever brought to market, including pembrolizumab, currently the world’s best-selling oncology therapeutic and arguably the most important anti-neoplastic agent ever introduced into clinical practice. While Drs. Perlmutter and Baynes’ track records do not provide a guarantee of future clinical success, and any products developed by us may not achieve the regulatory or commercial success of products that Drs. Perlmutter and Baynes were previously involved in developing, their experience provides valuable insight and strategic guidance to our drug development efforts. Our broader leadership team consists of former senior leaders at global pharmaceutical companies, who have successfully collaborated across several decades on the discovery, development, and commercialization of over 100 new molecular entities. Our strategy centers around deploying our technology platform, including our proprietary single molecule tracking, or SMT, system, to develop internally-derived novel therapies, while also leveraging the deep expertise of our management team to opportunistically in-license promising assets. Our most advanced product candidate, EIK1001, a toll-like receptor, or TLR, 7/8 dual-agonist, is currently in a global Phase 2/3 registrational trial in combination with pembrolizumab for the treatment of patients with advanced melanoma. This Phase 2/3 trial is designed to proceed to completion, subject to interim analysis by a data monitoring committee, and to form the basis for registration. We are also evaluating EIK1001 in combination with both pembrolizumab and histology appropriate chemotherapy for the treatment of patients with non-small cell lung cancer, or NSCLC, in a Phase 2 trial, as well as a Phase 2/3 registrational trial for which we recently initiated site selection. We are also conducting Phase 1/2 trials of each of our selective PARP1 inhibitor product candidates, EIK1003 and EIK1004, in ovarian, breast, prostate, and pancreatic cancers and, specifically with the brain-penetrant candidate EIK1004, to address brain metastases and primary brain malignancies. In addition, we have recently initiated a Phase 1/2 trial in patients with advanced solid tumors for EIK1005, our Werner, or WRN, helicase inhibitor that emerged through internal research using our technology platform, which will ultimately be evaluated for the treatment of patients with microsatellite instability-high, or MSI-high, tumors. We were incorporated in Delaware in July 2019. Our principal executive offices are located in Millbrae, California.

Nektar Therapeutics stock logo

Nektar Therapeutics NASDAQ:NKTR

$73.77 -1.19 (-1.59%)
Closing price 08/26/2026 04:00 PM Eastern
Extended Trading
$74.19 +0.42 (+0.58%)
As of 06:13 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in the field of immunotherapy in the United States and internationally. The company is developing rezpegaldesleukin, a cytokine Treg stimulant that is in phase 2 clinical trial for the treatment of systemic lupus erythematosus and ulcerative colitis, as well as phase 2b clinical trial to treat atopic dermatitis and psoriasis; and NKTR-255, an IL-15 receptor agonist, which is in phase 1 clinical trial to boost the immune system's natural ability to fight cancer. It has collaboration agreements with Takeda Pharmaceutical Company Ltd.; AstraZeneca AB; UCB Pharma S.A.; F. Hoffmann-La Roche Ltd; Bausch Health Companies Inc.; Pfizer Inc.; Amgen Inc.; UCB Pharma (Biogen); Bristol-Myers Squibb Company; Merck KGaA; and SFJ Pharmaceuticals, Inc. The company was incorporated in 1990 and is headquartered in San Francisco, California.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas